I found it 22MM shares at $0.75. So they could net $15MM in cash. which is about another year of working capital.
He's not dead weight. He's a great Operational guy just not a good CEO. AL MANN is a loyal guy and Hakan's been around for 14 years and probably has known Al longer. Al sees value in Hakan's knowledge and experience
I don't think SNY is screwing up the marketing. They only had 4 months to get Afreeza off the ground. It normally takes 12 - 16 months so they were behind the 8 ball. Add in the insurance timing and it makes things looks worse. Add in the SHORTS and the Establishments (Lily, Novo) they are trying everything in their power to see Afreeza fail.
I think we're fine. Once we get Tier 2 Coverage wich should happen before Feb. 2016 - We will be off to the races.
Which I'm sure is steep. MNKD will not have to pay back the $47MM thats on the LOC.
Funny how Jay Olsen did not ask Matt what the Term Fee is......
Then why is Sanofi hiring for the European Rollout? Go to LINKEDIN and search Afreeza and you will find the new International Director for Afreeza
Everyone make s good argument and I appreciate everyone's input but the problem is whether or not DCTH will make it financially. We all like the story and we're all regaining faith in Jennifer's leadership but the issue is will DCTH survive and will the stock recover. I would love to put more money into DCTH because of the potential but I don't know where the bottom is.
Jennifer talks about valuable milestones coming up in early 2016 but will that do anything to regain momentum in the stock. I've been in DCTH for 4 years and willing to go longer. Basically I'm in stock prison! Can DCTH regain compliance before the Bulletin Boards comes knocking?
Reverse stock splits are off the table unless the do a huge convertible deal (TOXIC) and run up the share count and then do a RS. Hobbs mentioned a PARTNER for the HCC Trial but the Phase 3 is probably 18 months away from starting.
I doubt it also but it's possible. I wonder with the EU Registry and Clinical DATA if they can use it for the Breakthrough Designation?
In defense of Hobbs he got screwed. The filter maker went out of business and the FDA lead him to believe they could submit the Gen 2 filter data with the NDA. FDA screwed DCTH and Hobbs.
But now Simpson is in charge and knows exactly what the FDA wants and hopefully the new P3 trial will be successful. The only problem is that we're talking about EOY 2017 - Mid year 2018 UNLESS..........the FDA gives them a fast track designation along with SPA and hopefully they can reduce the timing.
As long as JS tells a compelling story there will be investors. It will mean more dilution but then again this is a developmental company. FDA appvl is crucial for survival. Germany is good and it will keeps the lights on but to get this stock moving they cannot miss a beat with their projections. They've already delayed the OM Trial by 6 months. Was supposed to commence in Mid 2015.
There was some talk that a Phase 3 HCC/ICC Trial will come with a partner to help fund it. But first we have to get thru the OM Trial which will not get a read out until LATE 2017. So HCC is a LONG WAY OFF. They could get a partner and start the trial probably in mid 2017.
Debt financing will not be an option. It will most likely be convertible debt which in this day and time is considered TOXIC DEBT.
FDA approval for HCC & ICC is a 2018-19 event.
As long as they spin a good story they will get additional financing and dilution. As long as they don't have any debt they can raise money.
Expedited?? It took almost 3 years which is what HOBBS said 3 1/2 years ago.
Germany will basically keep the lights on until US approval. The stock will not move until there's a clear path to FDA approval which starts with the commencement of the NEW Phase 3 Gen 2 Filter.